
Maternal-fetal medicine specialist Dr. Michael Aziz shines a light on the leading complications for pregnant patients and why the US has the highest maternal mortality rate.

Maternal-fetal medicine specialist Dr. Michael Aziz shines a light on the leading complications for pregnant patients and why the US has the highest maternal mortality rate.

At Pri-Med West, primary care providers ask Dr. Michael Ziffra and Dr. Shirah Vollmer all the questions they have about treating mental illness and prescribing different classes of drugs.

A new study suggests a close examination of the medical histories of patients with generalized pustular psoriasis can make clear which are most likely to die or be hospitalized in the ICU.

Adolescents with a GLP-1 RA prescription within year of T2D diagnosis were more probable to be in better glycemic control and less probable to be prescribed insulin.

The inflammatory markers and leukocyte profiles detailed in the study had not been previously evaluated in any longitudinal studies.

Significantly more patients treated with upadacitinib achieved clinical remission compared to patients treated with placebo.

In patients with T2D, adding Gla-300 to GLP-1 RA significantly improved glycemic control without significantly increasing hypoglycemia.

Despite this, an increased incidence of mild to moderate oral candidiasis was also observed in the pooled data from 8 trials.

Dr. Shirah Vollmer and Dr. Michael Ziffra host a Question & Answer Session addressing common inquiries about mental health treatment in the primary care setting.

A continued discussion into misconceptions surrounding obesity treatments and how to better empower patients seeking out treatment.

Dr. Charles Vega suggestion doctors be less prescriptive in suggestion diets to patients.

Drugs like semaglutide are able to treat both diabetes and obesity.

A discussion into available pharmacotherapy for obesity and the uptake in practice of newer agents.

These findings suggest the importance of COVID-19 vaccination for patients with OHT.

The prevalence of sleep-disordered breathing differed across various etiologies of heart failure.

Dr. Michael Ziffra talked during Pri-Med West 2022 about some of the challenges and gaps in research needed for better bipolar disorder care.

There was no statistically significant difference in mean systolic blood pressure for the self-monitoring groups vs the usual care group.

Recent research has indicated that photos of skin can be used to assess AD severity.

Massachusetts General Hospital surgery resident Selena S. Li, MD, discusses her overseas volunteer work caring for refugees escaping their home during the Russia invasion.

Treating 100 older patients (≥60 years) with hypertension for approximately 3 years would prevent 1 major adverse cardiovascular event.

Sleep disordered breathing is frequently cited in patients with heart failure due to multiple factors included hypoxemia, sympathetic activation and systematic inflammation.

Investigators observed a potential risk between Black individuals with baseline signs of dehydration, SCT and related mortality over 30 years.

The study authors used data from Medicare beneficiaries who survived a heart attack between 1995 and 2019.

The daily oral combination therapy will be reconsidered for treating endometriosis pain this August.

Investigators believe that the BPDAI may under-estimate overall disease severity in darker skin types.

Investigators observed no reduction in readmission or mortality in a remote monitoring program with incentives for patients previously hospitalized for HF.

The Massachusetts General Hospital investigator discusses how LVADs and mechanical circulatory supports have altered the national heart donor strategy.

The study was specific to Olmsted County, Minnesota, and was the first American population-based study examining the association between hidradenitis suppurativa and these various conditions

The rate of long-term survival after 10 years in patients surviving the initial hospital stay after OHCA was between 62% and 64%.

Theresa R. Cerulli, MD, discusses the known clinical profile and evidential potential of the newest non-stimulant ADHD drug for adults.